Fig. 2.

Bestatin suppresses the LTB4 blood biomarker in CRC patients. (a) LTB4 serum concentration was evaluated in pre-treated and post-treated in bestatin-treated patients. LTB4 serum concentration in untreated patients was also measured at 0 and 7 days. Individual changes are show from day 0 to day 7. (b) The percentage of individual relative change in LTB4 from day 0 to day 7 is shown in a waterfall plot. (c) The relative change in LTB4 in the bestatin-treated group was compared with the untreated group. The data are shown as mean values ± S.E. (untreated group, n = 6; bestatin-treated group, n = 7).